The preliminary results of the phase II trial TRITON2 evaluating the efficacy of rucaparib in a preselected population with DDR defects in tumor or ctDNA showed PSA and radiographic responses in 48% and 45% of patients harboring BRCA2 defects. This evidence concerns the gene BRCA2 and neoplasm.